Home Companies Catalysts Deep Dives
Bepranemab PHASE2
Drug Profile
ModalityAntibody
RouteIV
Therapy AreaNeurology
Peak Sales Est$3000M
Formulations[]
Companies
UCB (ORIGINATOR)100%
Mechanism: Tau clearance
Expert: Targets and clears pathological tau protein aggregates
Everyday: Targets and clears pathological tau protein aggregates
Targets: ["TAU"]
Programs (1)
IndicationStageKey StudyRegional Status
Alzheimer's diseasePHASE2Phase 2a[]
Upcoming Catalysts (1)
Bepranemab - PSP/Alzheimer's - Ph2 - Updates 2026
Data from Supabase · Updated 2026-03-24